AU2001265219A1 - Methods and compositions for efficient gene transfer using transcomplementary vectors - Google Patents

Methods and compositions for efficient gene transfer using transcomplementary vectors

Info

Publication number
AU2001265219A1
AU2001265219A1 AU2001265219A AU6521901A AU2001265219A1 AU 2001265219 A1 AU2001265219 A1 AU 2001265219A1 AU 2001265219 A AU2001265219 A AU 2001265219A AU 6521901 A AU6521901 A AU 6521901A AU 2001265219 A1 AU2001265219 A1 AU 2001265219A1
Authority
AU
Australia
Prior art keywords
vectors
transcomplementary
compositions
methods
gene transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001265219A
Inventor
James N. Higginbotham
Charles J. Link Jr.
William J Ramsey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Gene Therapy Research Institute
Original Assignee
Human Gene Therapy Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Gene Therapy Research Institute filed Critical Human Gene Therapy Research Institute
Publication of AU2001265219A1 publication Critical patent/AU2001265219A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention includes a viral vector method and composition comprising transcomplementary replication incompetent viral vectors, preferably adenoviral vectors, which are cotransformed to a recipient cell. The two vectors complement each other and thus allow viral replication, in a synergistic combination which enhances both gene delivery and gene expression of genetic sequences contained within the vector.
AU2001265219A 2000-05-31 2001-05-31 Methods and compositions for efficient gene transfer using transcomplementary vectors Abandoned AU2001265219A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20824800P 2000-05-31 2000-05-31
US60208248 2000-05-31
PCT/US2001/017524 WO2001092550A2 (en) 2000-05-31 2001-05-31 Methods and compositions for efficient gene transfer using transcomplementary vectors

Publications (1)

Publication Number Publication Date
AU2001265219A1 true AU2001265219A1 (en) 2001-12-11

Family

ID=22773865

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001265219A Abandoned AU2001265219A1 (en) 2000-05-31 2001-05-31 Methods and compositions for efficient gene transfer using transcomplementary vectors

Country Status (6)

Country Link
US (2) US6875610B2 (en)
EP (1) EP1287153B1 (en)
AT (1) ATE444372T1 (en)
AU (1) AU2001265219A1 (en)
DE (1) DE60140052D1 (en)
WO (1) WO2001092550A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511534A (en) * 2001-10-16 2005-04-28 マグナム セラピューティクス インコーポレイテッド Self-replicating dual Ad vectors for vaccine and immunotherapy applications
EP1620538A4 (en) * 2003-04-29 2006-08-09 Cornell Res Foundation Inc Trasngenic expression of a phytochrome a gene
CN1327899C (en) * 2003-05-10 2007-07-25 彭朝晖 Gene recombined medicine of adenovirus carrier and p53 gene for treating proliferative diseases
EP2055316A1 (en) * 2003-09-09 2009-05-06 VIRxSYS Corporation Lentivirus vector-based approaches for generating an immune response to HIV in humans
SI2068918T1 (en) 2006-09-26 2012-09-28 Infectious Disease Res Inst Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN100593389C (en) * 2007-07-10 2010-03-10 清华大学 Continuous dynamic gathering type beastie inducing fluorescence molecule imaging system
CN102481312B (en) 2009-06-05 2015-07-15 传染性疾病研究院 Synthetic Glucopyranosyl Lipid Adjuvants
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TR201908003T4 (en) 2012-02-07 2019-06-21 Infectious Disease Res Inst Advanced adjuvant formulations containing TLR4 agonists and their method of use.
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
MX370573B (en) 2013-04-18 2019-12-17 Immune Design Corp Gla monotherapy for use in cancer treatment.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
ES2929054T3 (en) 2016-05-16 2022-11-24 Access To Advanced Health Inst Formulation containing a TLR agonist and methods of use
MX2018014399A (en) 2016-06-01 2019-06-06 Infectious Disease Res Inst Nanoalum particles containing a sizing agent.
KR20200066309A (en) 2017-09-08 2020-06-09 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Liposomal formulations containing saponins and methods of use
CN110964747A (en) * 2019-11-26 2020-04-07 深圳市人民医院 Suicide gene adenovirus with high-efficiency specific expression in glioma cell and construction method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1115414C (en) * 1993-07-13 2003-07-23 罗纳-布朗克罗莱尔股份有限公司 Defective adenovirus vectors and use thereof in gene therapy
EP1369487A3 (en) 1994-08-16 2004-04-07 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
JP4214239B2 (en) * 1996-11-19 2009-01-28 ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション Bifunctional retrovirus / adenovirus system
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
WO1999046371A2 (en) 1998-03-11 1999-09-16 Board Of Regents, The University Of Texas System Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
WO2000017376A1 (en) 1998-09-22 2000-03-30 The Governement Of The United States Of America, As Represented By The Secretary Of The Departement Of Health And Human Services Replication deficient retroviral vector system and methods of using
US6225113B1 (en) 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1059356B1 (en) 1999-06-09 2005-11-02 Universite Pierre Et Marie Curie Paris Vi Replicating retroviral constructs, preparation and uses for gene delivery

Also Published As

Publication number Publication date
EP1287153B1 (en) 2009-09-30
DE60140052D1 (en) 2009-11-12
US20020042139A1 (en) 2002-04-11
US7125549B2 (en) 2006-10-24
ATE444372T1 (en) 2009-10-15
US6875610B2 (en) 2005-04-05
US20060216271A1 (en) 2006-09-28
WO2001092550A2 (en) 2001-12-06
EP1287153A2 (en) 2003-03-05
WO2001092550A3 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
AU2001265219A1 (en) Methods and compositions for efficient gene transfer using transcomplementary vectors
WO2003080807A8 (en) Compositions and methods for suppressing eukaryotic gene expression
MXPA03000634A (en) Methods for the replacement, translocation and stacking of dna in eukaryotic genomes.
WO2002061097A8 (en) Cloning vectors and vector components
WO2005038033A8 (en) Cloning of cytochrome p450 genes from nicotiana
WO2002024232A3 (en) Pei: dna vector formulations for in vitro and in vivo gene delivery
WO2008028661A3 (en) Potexvirus- derived replicon
NO20052363L (en) Interferon-alpha polypeptides and conjugates
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2002077210A3 (en) Methods to culture circovirus
WO2002086144A3 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
WO2003093417A3 (en) Lentiviral vector particles resistant to complement inactivation
WO2002055709A3 (en) Rhodococcus cloning and expression vectors
ATE275956T1 (en) ALTERATION OF DNA METHYLTRANSFERASE THROUGH COMBINATION THERAPY
WO2003092582A3 (en) Chimeric ebola virus envelopes and uses therefor
WO2004024940A3 (en) Rna-mediated gene modulation
WO2002077249A3 (en) Type iii bacterial strains for use in medicine
WO2004018630A3 (en) Recombinant double-stranded rna phages and uses thereof
AU4835696A (en) Amplifying sequences, vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells, therapeutic and vaccine applications.
WO2003106625A3 (en) Hammerhead ribozymes
GB2379446A (en) Cells,culture methods and their uses
WO2001064912A3 (en) Triazine degrading enzymes
AU7794700A (en) Recombinant adenoviruses preparation and adenovirus banks
AU2294102A (en) Mutant muscle-specific enhancers
CA2487290A1 (en) Ehd1 gene promoting plant flowering and utilization thereof